Sanofi: New FV to adjust for new risk-free rate, LixiLan re-introduction and other smaller changes

BUY, Fair Value EUR92 vs. EUR84.5 (+9%)

News published on May Thursday 16, 2013
Share on

We are adjusting our FV on Sanofi. This is the consequence of different inputs into our model: on the negative side, disappointing figures in Q1 led to some minor downward adjustments (OTC, generics, BG Star) for a total of -EUR1/share; on the positive side, three elements: further phase III trials of sarilumab influences our probability of success revised up to 60% (+EUR1/share), re-introduction of LixiLan into our model following the reassuring tone from Sanofi during the Q1 conference call (+EUR2.5/share net impact), new risk-free rate adopted at BG of 3% vs. 3.3% (+EUR5/share). It is supporting our continuous confidence into Sanofi, one of our Top Picks in Q2 2013.

Full report available to subscribers
Please contact 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities